BUZZBERGThe leaderboard is ranked by Alpha Score, which weighs a speaker's average return, their number of calls, and reputation — a credibility rating of the source that can only raise a score, never lower it.Read the FAQ
Author remains highly bullish on Moberg Pharma, citing guaranteed US monetization for MOB-015 and estimating over 3x upside potential even excluding the US market.
Author bought QURE and is bullish on this basket of biotech names, citing very promising clinical data and a high likelihood of FDA approvals within the next 1-2 years.
High buyout probability for best-in-class obesity therapy.
Expects a high probability of a buyout for VKTX, driven by its best-in-class obesity and NASH clinical trials and the massive sales potential in the GLP-1 market.
Long SGN.WA for further upside to 100-105 PLN base-case fair value; the recent 20% move without news validates the overlooked-value thesis in a Polish software compounder with tiny free float and no analyst coverage, despite strong H1 revenue/profit growth.
moodywriter13 has 9 trade ideas tracked on Buzzberg across 9 tickers since March 2023. Ranked #154 on the Buzzberg Alpha leaderboard. Most covered: CPH.TO, MOB.ST, CLPT.
#154Ranked Speaker
#154 of 1655 voices on Buzzberg